Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab

Lee, A Y, Raya, A K, Kymes, S M, Shiels, A, Brantley, M A·2009·British Journal of Ophthalmology
DOI 10.1136/bjo.2008.150995

Cited by (134)

Items 101–134 of 134

  1. Genetik und Risikofaktoren der exsudativen AMD
    Martha Dietzel, Astrid Farwick, Hans‐Werner Hense · 2010 · Der Ophthalmologe
  2. Genetics in Age-Related Macular Degeneration
    Geoffrey Broadhead, Andrew Chang, Peter McCluskey · 2012 · Asia-Pacific Journal of Ophthalmology
  3. Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration
    Sarah N. Cheng, Theodore Leng · 2016 · Ophthalmic surgery, lasers & imaging retina
  4. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD)
    Nur Afiqah Mohamad, Vasudevan Ramachandran, Patimah Ismail, Hazlita Mohd Isa, Yoke Mun Chan, Nor Fariza Ngah, Norshakimah Md Bakri, Siew Mooi Ching, Fan Kee Hoo, Wan Aliaa Wan Sulaiman et al. · 2018 · Biomolecules and Biomedicine
  5. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis
    Amirhossein Roshanshad, Seyed Ali Moosavi, J Fernando Arevalo · 2024 · Ophthalmic Research
  6. Epidemiology and Risk Factors for Age-Related Macular Degeneration
    Johanna M. Seddon, Lucia Sobrin · 2012 · Elsevier eBooks
  7. Pharmacogenetic Association between Allelic Variants of the Autophagy-Related Genes and Anti-Vascular Endothelial Growth Factor Treatment Response in Neovascular Age-Related Macular Degeneration
    Oyuna S. Kozhevnikova, А. Ж. Фурсова, Anna S. Derbeneva, Ida F. Nikulich, Vasiliy A. Devyatkin, Nataliya G. Kolosova · 2023 · Biomedicines
  8. Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up
    Elvan Alper Şengül, Özgür Artunay, Rıfat Rasier, Alev Koçkar, Ceyda Afacan, Veysel Sabri Hançer, Erdal Yüzbaşıoğlu · 2017 · Ocular Immunology and Inflammation
  9. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?
    Jonathan Andrew Micieli · 2011 · Canadian Journal of Ophthalmology
  10. Degeneración macular relacionada a la edad
    X Trenchs Verdaguer · 2010 · Revista Médica Clínica Las Condes
  11. The Frequency of the Nonresponsiveness to Intravitreal Injection of the Anti-Vascular Endothelial Growth Factor Agent in Neovascular Age Related Macular Degeneration
    Burak Turgut · 2013 · International Journal of Ophthalmic Pathology
  12. Paradigm of Susceptibility Genes in AMD and PCV
    Moeen Riaz, Paul Nigel Baird · 2017 · Essentials in ophthalmology/Essentials ophthalmology
  13. Pharmacogenomics of Drugs in Ocular Therapeutics
    Thirumurthy Velpandian, Govindasamy Kumaramanickavel · 2016 · Springer eBooks
  14. Anti-VEGF Therapy for AMD: Results and Guidelines
    Paul Mitchell, Suriya Foran · 2012 · Springer eBooks
  15. Pharmacogenomics & its Application in Ophthalmology
    Surabhi Gupta, Sanjiv Kumar, Prafful Garg · 2015 · Delhi Journal of Ophthalmology
  16. Age-related macular degeneration treatment in the era of molecular medicine
    Rick N. Nordgren · 2014 · World Journal of Ophthalmology
  17. Anti VEGF Agents for Age Related Macular Degeneration
    Shani Golan, Michaella Goldstein, Anat Loewenstei · 2013 · InTech eBooks
  18. Pharmacogenomics in Ophthalmology
    Stephen G. Schwartz, Tomomi Higashide, Milam A. Brantley · 2013 · Springer eBooks
  19. Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD
    Daniel Lee, Clement K. Chan, Prema Abraham, David Sarraf · 2020 · European Journal of Ophthalmology
  20. Featured distribution of AMD-susceptibility SNPs between ethnicities and the modifying effect of SNPs on AMD therapy
    Huaijin Guan, Xiaozhao Yousef Yang, Jiangyan Hu, Hong Lü, Jingsheng Tuo · 2009 · Expert Review of Ophthalmology
  21. Anti-VEGF-Therapie der AMD: Ergebnisse und Leitlinien
    Paul Mitchell, Suriya Foran · 2011 · Springer eBooks
  22. The Complement System in AMD
    Peter Charbel Issa, Victor N. Chong, Hendrik P. N. Scholl · 2012 · Springer eBooks
  23. Das Komplementsystem bei der AMD
    Peter Charbel Issa, Victor N. Chong, Hendrik P. N. Scholl · 2011 · Springer eBooks
  24. Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors
    Dujon R.W. Fuzzard, Robyn H. Guymer, Robert Patrick Finger · 2016 · Essentials in ophthalmology/Essentials ophthalmology
  25. Genética del VEGF en la degeneración macular asociada a la edad
    Alfredo García‐Layana · 2010 · Elsevier eBooks
  26. The non-Responsiveness to Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Neovascularage-Related Macular Degeneration
    Burak Turgut · 2017 · Advances in Ophthalmology & Visual System
  27. Refractory Neovascular Age-related Macular Degeneration
    Dae Joong Ma, Hyeong Gon Yu · 2017 · Journal of Retina
  28. Role of genetic markers in personalization of anti-angiogenic therapy in patients with exudative age-related macular degeneration
    Larisa Konstantinovna Moshetova, Dmitry Alekseevich Sychev, E.R. Osmanova, Ksenia I. Turkina · 2017 · Russian Annals of Ophthalmology
  29. Genomics in Choroidal Neovascularization
    Kenji Yamashiro · 2020 · Springer eBooks
  30. Yaşa Bağlı Makula Dejenerasyonu ve Genetik
    Burçin Kepez Yıldız, Sibel Doğuizi, Abdullah Sezer · 2021
  31. Resistance to anti-angiogenic therapy in patients with neovascular age-related macular degeneration
    Mohamed Abdel Hamid, Sahar Torky Abdelrazik Abdelaziz, Ahmed Mohamed Sabry, Khaled Mourad, Azza A. Shehab · 2022 · Minia Journal of Medical Research
  32. Anti-VEGF Monotherapy Treatment Strategies for Neovascular AMD
    Jaclyn Lekse Kovach, Stephen G. Schwartz, Harry W. Flynn, Ingrid Ursula Scott · 2012 · Humana Press eBooks
  33. Glaucoma Pharmacogenetics
    Glaucoma Pharmacogenetics, Christoph Wolfgang Faschinger · 2012 · European Ophthalmic Review
  34. Nicotinamide Mononucleotide Attenuates Inflammatory Activation, Choroidal Neovascularization, and Lesion-Associated Remodeling
    Jue Wang, Hideto Osada, Steve Chen, Shintaro Yamaguchi, Kaori Hayashi, Kazuno Negishi, Toshihide Kurihara, Norimitsu Ban · 2026 · Investigative Ophthalmology & Visual Science